Integrative genomic analysis of temozolomide resistance in diffuse large β-cell lymphoma

Clinical Cancer Research

Volumn 20, Issue 2, 2014, Pages 382-392

  Leshchenko, Violetta V ^a   Kuo, Pei Yu ^a   Jiang, Zewei ^a   Thirukonda, Venu K ^b   Parekh, Samir ^a,b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; SMAD1 PROTEIN; TEMOZOLOMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RESISTANCE; DNA METHYLATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; EPIGENETICS; FEMALE; GENE EXPRESSION PROFILING; IN VITRO STUDY; IN VIVO STUDY; LARGE CELL LYMPHOMA; LYMPHOMA CELL LINE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; AZACITIDINE; CELL LINE, TUMOR; DACARBAZINE; DISEASE MODELS, ANIMAL; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENOMICS; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; PROMOTER REGIONS, GENETIC; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84892771471     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-0669     Document Type: Article

References (30)

1. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, et al. Inactivation of the DNA-repair geneMGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000;343:1350-4.
2. Plummer ER, Middleton MR, Jones C, Olsen A, Hickson I, McHugh P, et al. Temozolomide pharmacodynamics in patients with metastatic melanoma: DNA damage and activity of repair enzymes O6-alkylguanine alkyltransferase and poly(ADP-Ribose) polymerase-1. Clin Cancer Res 2005;11:3402-9.
3. Enting RH, Demopoulos A, DeAngelis LM, Abrey LE. Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. Neurology 2004;63:901-3.
4. Herrlinger U, Küker W, Platten M, Dichgans J, Weller M. First-line therapy with temozolomide induces regression of primary CNS lymphoma. Neurology 2002;58:1573-4.
5. Seiter K, Liu D, Loughran T, Siddiqui A, Baskind P, Ahmed T. Phase I study of temozolomide in relapsed/refractory acute leukemia. J Clin Oncol 2002;20:3249-53.
6. Tani M, Fina M, Alinari L, Stefoni V, Baccarani M, Zinzani P. Phase II trial of temozolomide in patients with pretreated cutaneous T-cell lymphoma. Haematologica 2005;90:1283-4.
7. Pegg AE, Dolan ME, Moschel RC. Structure, function, and inhibition of O6-alkylguanine-DNA alkyltransferase. Prog Nucleic Acid Res Mol Biol 1995;51:167-223.
8. Esteller M, Gaidano G, Goodman SN, Zagonel V, Capello D, Botto B, et al. Hypermethylation of theDNArepair gene O6-methylguanineDNA methyltransferase and survival of patients with diffuse large B-cell lymphoma. J Natl Cancer Inst 2002;94:26-32.
9. Khulan B TR, Ye K, et al. Comparative isoschizomer profiling of cytosine methylation: The HELP assay. Genome Res 2006;16: 1046-55.
10. Shaknovich R, Figueroa ME, Melnick A. HELP (HpaII tiny fragment enrichment by ligation-mediated PCR) assay for DNA methylation profiling of primary normal and malignant B lymphocytes. Methods Mol Biol 2010;632:191-201.
11. Thompson RF, Suzuki M, Lau KW, Greally JM. A pipeline for the quantitative analysis of CG dinucleotide methylation using mass spectrometry. Bioinformatics 2009;25:2164-70.
12. Ehrich M, Nelson MR, Stanssens P, Zabeau M, Liloglou T, Xinarianos G, et al. Quantitative high-throughput analysis of DNA methylation patterns by base-specific cleavage and mass spectrometry. Proc Natl Acad Sci U S A 2005;102:15785-90.
13. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Not as tenants in common Protoc 2009;4:44-57.
14. Kadoch C, Dinca EB, Voicu R, Chen L, Nguyen D, Parikh S, et al. Pathologic correlates of primary central nervous system lymphoma defined in an orthotopic xenograft model. Clin Cancer Res 2009;15: 1989-97.
15. 6-methylguanine-DNA methyltransferase promoter methylation in 45 primary central nervous system lymphomas: quantitative assessment of methylation and response to temozolomide treatment. J Neurooncol 2012;107(1):147-53.
16. Leone G, D'Alò F, Zardo G, Voso MT, Nervi C. Epigenetic treatment of myelodysplastic syndromes and acute myeloid leukemias. Curr Med Chem 2008;15:1274-87.
17. Tsai HC, Li H, Van Neste L, Cai Y, Robert C, Rassool FV, et al. Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell 2012;21:430-46.
18. Tawbi HA, Beumer JH, Tarhini AA, Moschos S, Buch SC, Egorin MJ, et al. Safety and efficacy of decitabine in combination with temozolomide in metastatic melanoma: A phase I/II study and pharmacokinetic analysis. Ann Oncol 2013;24:1112-9.
19. Clozel T, Yang S, Elstrom RL, Tam W, Martin P, Kormaksson M, et al. Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma. Cancer discovery 2013;3:100-19.
20. Uccella S, Cerutti R, Placidi C, Marchet S, Carnevali I, Bernasconi B, et al.MGMT methylation in diffuse large B-cell lymphoma: validation of quantitative methylation-specific PCR and comparison with MGMT protein expression. J Clin Pathol 2009;62:715-23.
21. Petrich AM, Leshchenko V, Kuo PY, Xia B, Thirukonda VK, Ulahannan N, et al. Akt inhibitors MK-2206 and nelfinavir overcome mTOR inhibitor resistance in diffuse large B-cell lymphoma. Clin Cancer Res 2012;18:2534-44.
22. Riedel RF, Porrello A, Pontzer E, Chenette EJ, Hsu DS, Balakumaran B, et al. A genomic approach to identify molecular pathways associated with chemotherapy resistance. Mol Cancer Ther 2008; 7:3141-9.
23. Iqbal J, Liu Z, Deffenbacher K, Chan WC. Gene expression profiling in lymphoma diagnosis and management. Best Pract Res Clin Haematol 2009;22:191-210.
24. Miyazawa K, Shinozaki M, Hara T, Furuya T, Miyazono K. Two major Smad pathways in TGF-beta superfamily signalling. Genes Cells 2002;7:1191-204.
25. Leshchenko VV, Kuo PY, Shaknovich R, Yang DT, Gellen7 T, Petrich A, et al. Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma. Blood 2010;116:1025-34.
26. Figueroa ME, Lugthart S, Li Y, Erpelinck-Verschueren C, Deng X, Christos PJ, et al. DNA methylation signatures identify biologically distinct subtypes in acute myeloid eukemia. Cancer Cell 2010; 17:13-27.
27. Kalac M, Scotto L, Marchi E, Amengual J, Seshan VE, Bhagat G, et al. HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL. Blood 2011;118:5506-16.
28. Ross S, Hill CS. How the Smads regulate transcription. Int J Biochem Cell Biol 2008;40:383-408.
29. Grady WM. Transforming growth factor-b, Smads, and cancer. Clin Can Res 2005;11:3151-4.
30. Pangas SA, Li X, Umans L, Zwijsen A, Huylebroeck D, Gutierrez C, et al. Conditional deletion of Smad1 and Smad5 in somatic cells of male and female gonads leads to metastatic tumor development in mice. Mol Cell Biol 2008;28:248-57.